Background: We designed allele-specific primers to amplify genomic DNA of patients with Charcot-Marie-Tooth 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP). Methods: Genomic DNA analysis was performed on 40 unrelated CMT1A duplication patients, 25 unrelated HNPP deletion patients, and 50 unaffected control individuals. The CMT1A and HNPP patients had previously been identified with microsatellite mapping. Results: Amplification products came to 3.6 kb in length from the normal proximal CMT1A repeated segment on chromosome 17p11.2 (proximal CMT1A-REP), 3.57 kb from the normal distal CMT1A repeated segment on chromosome 17p11.2 (distal CMT1A-REP), 3.6 kb from HNPP patients, and 3.58 kb from CMT1A patients. We could identify the mutations by means of agarose gel electrophoresis after polymerase chain reaction (PCR) amplification without restriction enzyme digestion from 33 of the 40 CMT1A and 19 of the 25 HNPP samples. Conclusion: Stringently specific primers were used to overcome the problem of nonspecific amplification and provide a rapid, all-or-none PCR product and efficient screening test for CMT1A and HNPP. [J Chin Med Assoc 2006;69(2): 68-73] 
Introduction
Charcot-Marie-Tooth (CMT) disease is the most frequent inherited peripheral neuropathy, with an estimated prevalence of approximately 1 in 2,500. 1 Two major forms of CMT can be identified electrophysiologically: one shows defects in the formation or maintenance of myelin (CMT1) and the other refers to primary axonal degeneration (CMT2). 2 A microduplication of 1.5 Mb containing the gene for peripheral myelin protein 22 (PMP22) on chromosome 17p11.2 is responsible for 75% of cases of the demyelinating form (CMT1A). [3] [4] [5] [6] [7] [8] [9] Diagnosis with markers located inside the duplication is usually carried out using restriction fragment length polymorphism (RFLP) probes 3, 4, 10 and poly(AC) repeats, 11, 12 less frequently with fluorescence in situ hybridization (FISH) analysis, 13 rapid real-time fluorescent polymerase chain reaction (PCR) gene dosage, 14 and multiplex ligation-dependent probe amplification (MLPA). 15 Molecular diagnosis often relies on the interpretation of differences in allele intensities, even with the most polymorphic markers that have been reported to date. When poly(AC) repeats are used for molecular diagnosis, artifact bands produced by slippage of the polymerase enzyme may lead to difficulties in interpretation of dosage for different alleles. Other useful diagnostic methods have been developed after extensive investigation of the 2 repeated 24-kb sequences (REPs) flanking the duplicated region. 16 A strategy with polymorphic short tandem repeats (STRs) located inside the CMT1A duplicated region that allows amplification with very low or no stuttering, accurate sizing, and visual quantification of allele intensity was used efficiently. 17 Recombination events leading to the CMT1A duplication occur almost entirely in 4 adjacent regions within 7.8 kb of the CMT1A-REP sequences, with a "hot spot" of recombination located in a 3.2-kb central segment defined by 2 restriction enzyme sites, EcoRI and SacI. 18, 19 Characterization of the junction fragment resulting from recombination allows positive identification of the duplication with RFLP probes on Southern blots. 18, 19 Several methods with direct allele-specific amplification of the junction fragments by PCR have also been reported. [20] [21] [22] [23] However, these methods were time-consuming and were used with restriction enzymes to define results. We developed an allelespecific, all-or-none and rapid PCR method to detect the junction fragments of CMT1A and hereditary neuropathy with liability to pressure palsies (HNPP).
Methods
Genomic DNA analysis was performed on 40 unrelated CMT1A duplication patients, 25 unrelated HNPP deletion patients, and 50 unaffected control individuals. The CMT1A and HNPP patients had previously been identified with microsatellite mapping: (ATCT)3AT(ATCT)6(ACCT)5 (GenBank accession no. AC005703), (CAATA)14 (GenBank accession no. AC0013248), (TTTC)12 (GenBank accession no. AC0013248), D17S122 (RM11GT), and D17S921(afm191xh12). 17, 24 The CMT1A and HNPP PCR assays described here were carried out in a blind study. Informed consent was obtained from all subjects recruited in this study before genetic testing.
Genomic DNA was extracted from peripheral lymphocytes. 25 The following allele-specific primers were designed according to the published proximal and distal CMT1A-REP sequences (GeneBank accession no. U41165-distal and U41166-proximal): Hot-DF 5' TTGGATTCACAGAGACATTAGTGTTAC-3'; Hot-DR 5'-TAGTAGAGTGAGTACAGTGGAC-3'; Hot-PF 5'-TTGGATTCAAAGATATTAGTGTTAT-3'; Hot-PR 5'-TAGTAGAGCTCACTCTACAG-3'.
The primers Hot-DF and Hot-DR were used for the normal distal CMT1A-REP, the primers Hot-PF and Hot-PR were used for the normal proximal CMT1A-REP, the primers Hot-DF and Hot-PR were used for the junctional CMT1A repeated fragment, and Hot-PF and Hot-DR were used for the junctional HNPP repeated fragment.
Amplification was carried out in 30 µL of 1.5 mM MgCl 2 , 50 pmol of each primer, 250 µmol of each dNTP, 50 ng template DNA, and 2.5 units Taq DNA polymerase (Takara Bio Inc., Shiga, Japan). The PCR buffer (10×) was composed of 100 mM Tris-HCl (pH 8.3), 500 mM KCl, and 15 mM MgCl 2 . Amplification was done by initial denaturation at 94°C for 5 minutes followed by 25 cycles of 30 seconds at 94°C, 1 minute at 56°C, and 3 minutes at 72°C, including a 1-second autoextension function on the extension time with a final extension of 5 minutes at 72°C using a PTC-200 Peltier thermal cycler (MJ Research, Watertown, MA, USA). Amplified products were digested with EcoRI and NsiI (New England Biolabs, Beverly, MA, USA) according to the manufacturer's instructions and electrophoresed in 1% agarose gels. Gels were stained in ethidium bromide (0.1 µg/mL) and visualized under UV light.
Results
The normal distal and proximal CMT1A-REP PCR assay amplified 3.57-and 3.6-kb segments, respectively, from 50 normal subjects, 40 CMT1A patients, and 25 HNPP patients using Hot-DF and Hot-DR or Hot-PF and Hot-PR primers. The CMT1A PCR assay amplified a 3.58-kb junctional CMT1A-REP fragment using primers Hot-DF and Hot-PR. However, there was no PCR product in 50 normal subjects and 25 HNPP patients using this pair of primers. In the HNPP PCR assay, a 3.6-kb junctional CMT1A-REP fragment was amplified using primers Hot-PF and Hot-DR. Furthermore, there was no PCR product in 50 normal subjects and 40 CMT1A patients (Figure 1) .
Those PCR products of normal distal CMT1A-REP, normal proximal CMT1A-REP, junctional CMT1A, and HNPP fragments could be further digested with EcoRI and NsiI to confirm their effective amplification. The normal distal CMT1A-REP segment could be digested by EcoRI, but not NsiI, to generate 3.17-and 0.4-kb fragments. The normal proximal CMT-REP segment could be digested by NsiI, but not EcoRI, to generate 2.1-and 1.5-kb fragments. The junctional CMT1A fragment could be digested by EcoRI and NsiI to generate 1.7-, 1.5-, and 0.4-kb fragments. The junctional HNPP fragment could not be digested by EcoRI or NsiI (Figure 2 ). 
Discussion
Using our method, we have detected 82.5% of CMT1A and 76% of HNPP patients in this study. Since the duplication of the PMP-22 gene accounts for 70.7% of cases of CMT1 and deletion of the PMP22 gene was present in 84% of the HNPP patients, 9,23 screening for PMP22 gene duplications/deletions obviously should be the first approach in diagnosing hereditary demyelinating neuropathy.
Currently available techniques for detecting gene duplication or deletion are laborious and have specific drawbacks. Southern blot analysis is a labor-intensive technique involving the use of radioisotopes, chemiluminescence, or silver staining. In addition, partial digestion and/or degradation of the genomic sample can be problematic. The disadvantage of pulsed field gel electrophoresis (PFGE) analysis is the need for sophisticated equipment and fresh cells or blood samples. Dosage analysis using polymorphic alleles depends on the informativeness of the marker. Although PCR-based microsatellite analysis is an improvement on previously used RFLP probes, the interpretation of results can be difficult, often requiring quantitative analysis, and is time-consuming in comparison with our method. FISH technology is complex and requires costly apparatus that is not always available in every DNA diagnostic laboratory. The development of rapid simple PCR-based tests for the diagnosis of CMT1A and HNPP would, therefore, help improve molecular diagnostic services such as prenatal or postnatal diagnostic tests. 23 Haupt et al 20 described a PCR-based test using primers designed to exclusively amplify either the novel CMT1A or HNPP hybrid fragments. In their method, however, amplification products were also obtained from the nonrecombinant CMT1A-REP regions. Double restriction enzyme digestion of the PCR products was, therefore, required to distinguish between normal CMT1A and hybrid CMT1A-specific repeat (hybrid CMT1A-REP). These assays detected recombination events within the 1.7-kb hotspot located between an NsiI site that is unique to the proximal CMT1A-REP and an EcoRI site that is unique to the distal CMT1A-REP. The expected detection rate within this region was 76.9% in CMT1A and 71.9% in HNPP patients. 26 Chang et al 27 described a similar test for CMT1A in which junction-specific primers were used to amplify the novel 3.2-kb hybrid fragments. No amplification product was produced in healthy individuals and in those patients with crossover breakpoints outside the 3.2-kb region. Although this produced reliable results, the workload per sample was still approximately twice that of the CMT1A test we describe here. Stronach et al 22 designed a PCR-based test that amplified a 3.6-kb region, including the 1.7-kb hotspot from specific CMT1A-REPs. Double restriction analysis was still required to distinguish normal and hybrid CMT1A-REPs. Although they extended the breakpoint region to 3.2 kb and increased the detection rate to 80% for CMT1A and 95% for HNPP, 22 they could not overcome the problem of nonspecific amplification. 18, 22 We used the allele-specific primers Hot-DF and Hot-PR for the CMT1A test, and Hot-PF and Hot-DR for the HNPP test, therefore ensuring specific amplification of the hybrid fragments only. This overcomes the problem of nonspecific amplification described by Haupt et al. 20 It is important to note that the methods we used are expected to detect, at most, 82.5% of the patients with CMT1A duplication and 76% of the patients with HNPP deletion. A negative result, therefore, does not exclude the possibility of the diagnosis. In such cases, multiple unrelated techniques such as microsatellite, 17, 24 Southern blot, 3, 28 or MLPA 15 have to be employed in order to confirm or exclude duplication or deletion of a copy of the PMP22 gene. The negative results may have resulted from infrequent variation in the CMT1A-REP sequences, [29] [30] [31] chimerism of the duplication junction fragments, 32 or possible recombination outside the CMT1A-REP sequences. 33, 34 Additionally, as with any PCR-based technique used in a diagnostic setting, it is important to include suitable controls against PCR contamination, as well as positive and negative controls for the enzymatic digests.
In summary, in this study, stringently specific primers (Hot-PF, Hot-PR, Hot-DF, and Hot-DR) were used to overcome the problem of nonspecific amplification seen in other similar, previously published PCR-based techniques and provide a rapid, all-or-none and efficient screening test for CMT1A and HNPP.
